Holen Sie sich die Stockscreener-App
6.57
2.50%
0.16
Handel nachbörslich:
6.57
Schlusskurs vom Vortag:
$6.41
Offen:
$6.38
24-Stunden-Volumen:
2.02M
Relative Volume:
2.28
Marktkapitalisierung:
$513.45M
Einnahmen:
$380.79M
Nettoeinkommen (Verlust:
$49.27M
KGV:
9.3857
EPS:
0.7
Netto-Cashflow:
$10.68M
1W Leistung:
+4.95%
1M Leistung:
+28.82%
6M Leistung:
+68.03%
1J Leistung:
+277.59%
1-Tages-Spanne:
$6.31
$6.855
1-Wochen-Bereich:
$6.08
$6.855
52-Wochen-Spanne:
$1.62
$7.27
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Firmenname
Amylyx Pharmaceuticals Inc
Sektor
Branche
Telefon
617-683-0917
Adresse
43 THORNDIKE STREET, CAMBRIDGE
Vergleichen Sie AMLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
6.57 | 513.45M | 380.79M | 49.27M | 10.68M | 0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-30 | Eingeleitet | TD Cowen | Buy |
| 2025-04-07 | Hochstufung | Mizuho | Neutral → Outperform |
| 2024-11-18 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-03-18 | Herabstufung | Mizuho | Buy → Neutral |
| 2024-03-11 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-07-24 | Hochstufung | Goldman | Neutral → Buy |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-01-05 | Eingeleitet | BofA Securities | Buy |
| 2022-05-25 | Eingeleitet | Citigroup | Buy |
| 2022-04-01 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Amylyx Pharmaceuticals Inc Aktie (AMLX) Neueste Nachrichten
Amylyx Pharmaceuticals (NASDAQ:AMLX) Coverage Initiated by Analysts at Citigroup - Defense World
Citi initiates Amylyx stock with buy rating on promising pipeline By Investing.com - Investing.com South Africa
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Citi initiates Amylyx stock with buy rating on promising pipeline - Investing.com
Amylyx Pharmaceuticals (AMLX): Citigroup Initiates Coverage with 'Buy' Rating | AMLX Stock News - GuruFocus
Amylyx initiated with a Buy at Citi - TipRanks
Amylyx (AMLX) Gains Positive Outlook with New Analyst Coverage | AMLX Stock News - GuruFocus
Diabetes Insipidus Market Statistics Expected to Experience - openPR.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Amylyx gets FDA fast track status for ALS treatment - MSN
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Buy” by Brokerages - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Investors to Inquire about Securities Investigation - ACCESS Newswire
# H.C. Wainwright reiterates Buy rating on AMYLYX stock ahead of trial - Investing.com India
Optimistic Buy Rating for Amylyx Pharmaceuticals’ AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights - TipRanks
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Reach Out - ACCESS Newswire
AMX0114 receives FDA fast track status for the treatment of ALS - ALS News Today
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Wellington Management Group LLP Purchases New Stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Ameriprise Financial Inc. Purchases Shares of 50,428 Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals Inc Holds Annual Stockholder Meeting - TipRanks
Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News
DEADLINE ALERT: Bernstein Liebhard LLP Reminds Amylyx Pharmaceuticals, Inc. Investors of Upcoming Deadline - ACCESS Newswire
FDA fast tracks Amylyx’s ALS drug candidate AMX0114 By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Encourages Amylyx Pharmaceuticals, Inc. (AMLX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis - BioSpace
Amylyx Pharmaceuticals' Potential ALS Treatment Gets FDA Fast Track Designation - marketscreener.com
Amylyx (AMLX) Gains FDA Fast Track Status for ALS Treatment | AM - GuruFocus
FDA fast tracks Amylyx’s ALS drug candidate AMX0114 - Investing.com
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Purchased by Millennium Management LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Northern Trust Corp Purchases 11,214 Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Amylyx Pharmaceuticals (NASDAQ:AMLX) Now Covered by TD Cowen - Defense World
TD Cowen starts Amylyx stock coverage with Buy rating - Investing.com Australia
Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Pot - GuruFocus
TD Cowen starts Amylyx stock coverage with Buy rating By Investing.com - Investing.com Nigeria
Amylyx (AMLX) Receives Buy Rating from TD Cowen on Avexitide Potential | AMLX Stock News - GuruFocus
Amylyx initiated with a Buy at TD Cowen - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect - ACCESS Newswire
2025-05-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Investors to Connect | NDAQ:AMLX | Press Release - Stockhouse
Amyotrophic lateral Sclerosis Market 2025-2032: Top Trends & - openPR.com
🌐 ALS Treatment Market to Hit $1.04 Billion by 2032 | Driven by New Drug Approvals & Asia-Pacific Expansion - openPR.com
Man Group plc Trims Stock Position in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bank of America Corp DE Increases Stock Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Amylyx Pharmaceuticals, Inc. (AMLX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences - BioSpace
Finanzdaten der Amylyx Pharmaceuticals Inc-Aktie (AMLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amylyx Pharmaceuticals Inc-Aktie (AMLX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bedrosian Camille L | Chief Medical Officer |
Mar 31 '25 |
Sale |
3.47 |
12,425 |
43,082 |
194,375 |
| Mazzariello Gina | Chief Legal Officer |
Mar 31 '25 |
Sale |
3.48 |
9,192 |
31,954 |
187,969 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.47 |
21,490 |
74,482 |
3,355,280 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 31 '25 |
Sale |
3.46 |
21,490 |
74,454 |
3,355,276 |
| Zeiher Bernhardt G | Director |
Mar 20 '25 |
Buy |
3.70 |
10,000 |
37,005 |
10,000 |
| Klee Justin B. | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.15 |
4,595 |
14,483 |
3,196,648 |
| Cohen Joshua B | Co-Chief Executive Officer |
Mar 03 '25 |
Sale |
3.17 |
4,595 |
14,549 |
3,196,652 |
| Mazzariello Gina | Chief Legal Officer |
Mar 03 '25 |
Sale |
3.12 |
1,611 |
5,022 |
133,310 |
| Mazzariello Gina | Chief Legal Officer |
Feb 24 '25 |
Sale |
3.15 |
4,169 |
13,145 |
134,921 |
| Klee Justin B. | Co-Chief Executive Officer |
Feb 05 '25 |
Option Exercise |
1.57 |
36,310 |
57,007 |
3,201,243 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):